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Atrial fibrillation (AF) is the most common sustained
cardiac arrhythmia, affecting 1% to 2% of the populations of
North America and Europe and up to 9% of people 80
years of age (1,2). Appropriate recognition and treatment
can diminish the likelihood of its 2 most serious complica-
tions, stroke and heart failure (3). The great majority of AF
is attributable to underlying structural heart disease, al-
though lone AF (without pre-existing or coexisting coro-
nary heart disease, heart failure, rheumatic heart disease, or
hypertensive cardiovascular disease) was the diagnosis in
11.4% of patients with AF in the Framingham cohort (4).
Even with subclinical AF, a recent study in patients age 
65 years with histories of hypertension and newly implanted
dual-chamber pacemakers or implantable cardioverter-
defibrillators highlighted the increased risk for stroke, com-
pared with those without such paroxysms of arrhythmia (5).
Because of the global health burden of AF and its associated
complications, identification of those who are most likely to
experience this condition should lead to improved diagnosis
and management.
See page 1173
The causes of lone AF remain unclear. Astute investiga-
tors have recognized familial occurrence despite low pen-
etrance, and standard genetic techniques have led to the
identification of several chromosomal loci and genes in
which mutations can cause dominantly inherited AF. These
include genes encoding myocardial potassium (KCNQ1,
KCNA5,KCNE5,KCNJ2, andKCNE2) and sodium (SCN5A,
CN1B, SCN2B, and SCN3B) channels, potassium–adenosine
riphosphate channels (ABCC9), nucleoporin-155 (NUP155),
ap junction protein connexin 40 (GJA5), and atrial natriuretic
eptide (NPPA) (6–17). Single-nucleotide polymorphisms
SNPs) on chromosome 4q25 were initially recognized in
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ide association studies that were performed in Iceland (18).
his association was replicated in several other cohorts with
uropean ancestry as well as among Han Chinese patients
ith AF (18,19). The rs2200733-T allele carries an odds ratio
or AF of 1.90 in combined analysis of several cohorts (p 
.3  1013) (19).
In this issue of the Journal, Ritchie et al. (20) from
anderbilt University use a robust AF registry to investigate
he genetic basis and penetrance of familial AF. In a cohort
ith lone AF, deoxyribonucleic acid (DNA) sequence
nalysis was performed for KCNQ1 and KCNA5 in 231
robands, NKX2-5 in 160, SCN5A in 118, and NPPA in 98.
The investigators identified 11 families in which AF was
present in 2 people who also shared a possible DNA
mutation in 1 of these genes. The penetrance of AF in
family members who carried the putative mutation was low
and age dependent, consistent with prior reports (21).
Addition of the chromosome 4q25 SNP genotypes helped
predict whether the carriers of these rare variants would
develop AF.
Their findings are interesting but should be considered
with some caution. First, are these rare DNA variants truly
responsible for familial AF in these families? For instance,
SCN5A p.L461V was found in 3 affected relatives in family
AF242. Another group found this variant in a patient with
sudden cardiac death, yet it failed to segregate with disease
in the family (22). The National Heart, Lung, and Blood
Institute’s Exome Variant Server (23) indicates a minor
allele frequency of 0.89% in African Americans. Does that
exclude it as responsible or functional? It certainly does not;
yet functional evidence of its pathogenicity would help.
Similarly, p.A572D in SCN5A, p.insAP54-56 in KCNQ1,
nd p.S64L in NPPA have all been seen in “controls.”
unctional studies of p.A572D demonstrated no effect
nless the minor allele of a more common SCN5A variant,
.H558R, was also present (24). These 2 SCN5A variants
ppear to be linked, and R558 (the minor allele) is also
ssociated with AF (25). At this point, p.A572D in SCN5A
hould be considered a rare polymorphism whose signifi-
ance is unknown.
Who constitutes an appropriate negative control for an
F genetics study? Even carefully phenotyped controls
ithout known paroxysms of prior AF may experience it
ater in life. For a disorder as common and complex as AF,
e must keep in mind that contributory DNA variants
robably occur with similar prevalence as AF. Pathogenicity
imply cannot be determined by the rarity of a novel DNA
ariant or its cosegregation with AF in a small family. A
ariant such as NPPA p.A117V may seem like a minor
hange, because alanine is very similar to valine, but the
-to-T alteration in DNA might create cryptic splicing,
ith introduction of a GT sequence that could create a 5=
plice donor. Once again, in the absence of functional data, the
ignificance of these rare DNA variants remains unknown.
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ence the development of AF? This also is an area of active
investigation without clear answers today. These seemingly
innocuous variations in intronic DNA sequences do not
directly alter the amino acid sequence in any protein, but
they occur in a highly conserved locus among many species.
This suggests that they act as markers of nearby functional
or regulatory elements (26). PITX2 is the closest gene in
proximity, and it encodes a homeobox protein that is
expressed in developing myocardium, perhaps contributing
to cardiomyoblast proliferation and myogenesis (27). This
gene is widely expressed in the developing embryo, contrib-
uting to left-right signaling (28). Dominant mutations in
this gene result in Axenfeld-Rieger syndrome, which is
characterized by ocular, craniofacial, dental, and periumbil-
ical abnormalities (28). But the interval between the SNP
with the strongest association to AF (rs2200733) and
PITX2 is 146,890 base pairs, on the basis of the latest
annotation of the human genome. Despite overwhelming
evidence of a modest effect on AF mediated by this
chromosomal locus, the mechanism remains a mystery at
this point.
Since completion of the first whole human genome
sequencing more than a decade ago, improvements in
technology have dramatically accelerated the efficiency with
which DNA analysis can be performed. Early (Maxam-
Gilbert) DNA sequencing with isotope-labeled fragments
of DNA was replaced by dideoxy (Sanger) sequencing,
followed by chip-based platforms and subsequently “next-
generation” technologies. These include polony sequencing,
pyrosequencing, sequencing by ligation, and nonoptical ion
sensing techniques (29). Today, robust sequencing of enor-
mous amounts of DNA can be performed at a fraction of
the costs required just a few years ago. Next-generation
sequencing technologies are now used in many clinical
(Clinical Laboratory Improvement Amendments–certified)
laboratories, and cardiovascular diseases in particular are
deemed ripe for the expanding use of genetic testing in
clinical practice.
Currently, approximately 50% of the genes in which
mutations cause familial AF are available for clinical genetic
testing in the U.S., and that list will certainly grow.
Genotyping for a panel of common SNPs, including the
chromosome 4q25 rs2200733 and rs10033464 makers, is
also clinically available. Yet recently published guidelines
classify genetic testing for AF as “Class III (is not indicated/
recommended),” specifically also commenting on SNP
genotyping as “not indicated at this time based on the
limited outcome data currently available” (30). Acknowl-
edging that AF genetics is complex and that there is no role
for genetic testing for most people with AF, Ritchie et al.
(20) also suggest that a case can be made for genetic testing
in the setting of early-onset familial or lone AF. Such an
optimistic perspective regarding the clinical application of
genetic testing should not be taken as a consensus opinion,
because the risks of misinterpretation are high, and thetherapeutic value in the context of such uncertainly seems
quite low.
Looking toward the future, costs for genetic analysis will
continue to decline. Better recognition of the pathogenic
effects of both rare and common DNA variants will improve
our ability to interpret such sequencing, and the use of
genetic testing will continue to grow. As cardiologists, we
must be prepared for the rapidly expanding role of genetic
analysis in clinical practice, yet we should remain skeptical
about its use for complex disorders, such as AF, until larger
studies demonstrate clear utility.
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